secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001213900-24-038756
Event type: earnings
Sentiment:  neutral
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q1 net loss $11.1M; cash runway into 2026 after $42M private placement
--------------------------------------------------------------------------------

- Q1 net loss $11.1M ($0.97/sh) vs $9.0M ($0.80/sh) YoY; R&D spend rose to $7.7M from $5.1M.
- Cash, equivalents and marketable securities $55.2M at Mar 31, 2024; combined with $42M net from April PIPE funds operations into 2026.
- TARA-002 in NMIBC: 3-month CR rate 38% overall; 63% in CIS-only; no Grade 3+ related AEs.
- ADVANCED-2 interim data (BCG-unresponsive/naïve) expected 2H 2024; registrational path aligned with FDA guidance.
- FDA aligned on registrational path for IV Choline Chloride as choline source for PN-dependent patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/0001213900-24-038756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/ea0204875-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-038756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer